All Updates

All Updates

icon
Filter
Funding
Alumis to raise USD 300 million in IPO for advancing clinical trials of TYK2 pipeline
Precision Medicine
Jun 24, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jun 24, 2024

Alumis to raise USD 300 million in IPO for advancing clinical trials of TYK2 pipeline

Funding

  • Alumis has revealed its plan to raise ~USD 300 million from an initial public offering (IPO) by issuing 17.65 million shares, with a target price between USD 16 and USD 18 per share. Foresite Capital Management, Baker Brothers Life Sciences LP, and AyurMaya Capital Management Fund LP are listed as principal shareholders of the IPO. After the IPO, Alumis plans to begin trading on Nasdaq under the ticker symbol, "ALMS."

  • The company expects to use the funds to support the Phase III psoriasis clinical trials of its lead candidate allosteric tyrosine kinase 2 (TYK2) inhibitor called "ESK-001" and to complete ongoing Phase II trials in a type of eye inflammation called "uveitis," as well as in systemic lupus erythematosus.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.